TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
| Website: | www.tgtherapeutics.com |
| Email: | ir@tgtxinc.com |
| Main Phone: | +1 212 554-4484 |
| Address: | 2 Gansevoort Street |
| Address 2: | 9th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | US |
| Postal Code: | 10014 |
| Exchange: | NSC |
| CEO: | Michael S. Weiss |
| Employees: | 134 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Umbralisib is in Phase 3 trials in hematologic malignancies.
First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH). (Image: Novimmune)
Data presented at ECTRIMS, the world's largest MS conference
Christmas comes but once a year, but a portfolio with huge returns is the gift that just keeps on giving. That’s why we’re taking the end of the year to look back at those investments
Stock in TG Therapeutics (TGTX) popped in Wednesday trading, seeing shares bounce 9.11%. Driving the gains appears to be the favorable deal secured by rival Infinity (INFI) with AbbVie (ABBV)
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Since their introduction over the past decade, Exchange Traded Funds (ETFs) have quickly established themselves as a standard and highly sought-after financial instrument for investors.ETFs are
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
| Website: | www.tgtherapeutics.com |
| Email: | ir@tgtxinc.com |
| Main Phone: | +1 212 554-4484 |
| Address: | 2 Gansevoort Street |
| Address 2: | 9th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | US |
| Postal Code: | 10014 |
| Exchange: | NSC |
| CEO: | Michael S. Weiss |
| Employees: | 134 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Umbralisib is in Phase 3 trials in hematologic malignancies.
First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH). (Image: Novimmune)
Data presented at ECTRIMS, the world's largest MS conference
Christmas comes but once a year, but a portfolio with huge returns is the gift that just keeps on giving. That’s why we’re taking the end of the year to look back at those investments
Stock in TG Therapeutics (TGTX) popped in Wednesday trading, seeing shares bounce 9.11%. Driving the gains appears to be the favorable deal secured by rival Infinity (INFI) with AbbVie (ABBV)
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Since their introduction over the past decade, Exchange Traded Funds (ETFs) have quickly established themselves as a standard and highly sought-after financial instrument for investors.ETFs are
| Last Price 29.84 | Change $ -0.252 | Change % -0.84 | Tick N/A |
| Bid 29.82 | Bid Size 200.00 | Ask 29.89 | Ask Size 100.00 |
| Open 29.92 | High 30.52 | Low 29.36 | Prev Close 30.09 |
| Last Trade | Volume 624,219 | 52 Wk Hi 31.97 | 52 Wk Low 6.35 |
| Market Cap 3.9 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 131,490,195.00 | EPS (TTM) -2.09 | PE Ratio -14.30 | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 12 |
| Number of Buys | 0 | 8 |
| Number of Sells | 0 | 4 |
| Net Activity | 0 | 552895 |
| Last 10 Buys | Shares |
|---|---|
| Michael S. Weiss | 1,000 |
| Neil Herskowitz | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| Michael S. Weiss | 1,000 |
| Michael S. Weiss | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| William J. Kennedy | 1,000 |
| Laurence N. Charney | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| William J. Kennedy | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 38 | 38 | 38 | 38 |
| Low Target Price Estimate | 22 | 22 | 22 | 22 |
| Mean Target Price Estimate | 29.67 | 29.67 | 29.67 | 29.67 |
| Standard Deviation | 7.34 | 7.34 | 7.34 | 7.34 |
| Date of Most Recent Estimate | 06/04/18 | 05/25/18 | 05/11/18 | 06/04/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-13 |
| 8-K | Report of unscheduled material events or corporate changes. | 24 | 2018-06-07 |
| 8-K | Report of unscheduled material events or corporate changes. | 13 | 2018-06-04 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 54 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 6 | 2018-05-08 |
| CT ORDER | 1 | 2018-04-30 | |
| DEFA14A | Additional proxy soliciting materials - definitive | 5 | 2018-04-30 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 49 | 2018-04-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-04-24 |
| 10-K | Annual report with a comprehensive overview of the company | 141 | 2018-03-15 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait